Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced the appointment of John Heffernan, a pharmaceutical industry veteran, to the newly created position of Vice President of Manufacturing. Mr. Heffernan has a breadth of experience in all facets of manufacturing in the cell therapy space.

“We are very pleased to attract someone of John’s caliber to our company at this time in our growth as we progress our novel programs to treat Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Degeneration (Dry AMD). His wide ranging experience with leading and innovative biotechnology companies, will prove to be highly valuable to us as we prepare to initiate Phase 2 clinical trials for our lead programs in dry AMD and SMD,” said Paul K. Wotton, President and Chief Executive Officer of Ocata.

Prior to joining Ocata, Mr. Heffernan was with Genzyme for 18 years in the Cell Therapy and Regenerative Medicine business unit. His most recent position was Vice President of Global Operations with facilities in Europe, Australia and US. In his 35 year career Mr. Heffernan has also held manufacturing positions with Gene-Trak, Behring Diagnostics, Boston Scientific and Baxter. Mr. Heffernan earned a master’s degree in business administration with a focus in Operations from Suffolk University and a bachelor’s degree in Biology from Stonehill College.

“I am thrilled to join Ocata at this time, a company that is a leader in the development and manufacture of cell therapy based therapeutics and I look forward to working with the team to advance manufacturing operations in support of our late stage clinical development programs and ultimately their potential commercialization,” commented Mr. Heffernan.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

Forward-Looking Statements

All statements, other than historical facts, contained in this news release, including statements regarding the relevance and applicability of clinical trials, potential new applications of and expanded indications covering Ocata’s technology, the effect of Ocata’s products on the medical needs and quality of life of study subjects or other patients, Ocata’s potential product pipeline and development efforts, and any other statements about Ocata’s future expectations, beliefs, goals, plans, results or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the fact that Ocata has no product revenue and no products approved for marketing; Ocata’s limited operating history;, the need for and limited sources of future capital; potential failures or delays in obtaining regulatory approval of products; risks inherent in the development and commercialization of potential products; reliance on new and unproven technology in the development of products; the need to protect Ocata’s intellectual property; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company’s product candidate claims; even if approved, the risk that physicians and patients may not accept or use Ocata’s products; Ocata’s reliance on third parties to conduct its clinical trials and to formulate and manufacture its product candidates; and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Ocata’s periodic reports, including the Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2014. Forward-looking statements are based on the beliefs, opinions, and expectations of Ocata’s management at the time they are made, and Ocata does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of Ocata’s management at the time they are made, and Ocata does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that Ocata’s future clinical trials will be successful or that the results of previous clinical studies will lead to commercialization or products or therapies.

Investors:Westwicke PartnersJohn Woolford, 443-213-0506john.woolford@westwicke.comorPress:Russo PartnersDavid Schull, 858-717-2310david.schull@russopartnersllc.com

Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ocata Therapeutics, Inc. Charts.
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ocata Therapeutics, Inc. Charts.